Shares of OptimizeRx Corporation tumbled after the company cut its guidance, even as its third-quarter results exceeded analyst expectations.
On Thursday premarket, OptimizeRx plunged nearly 22%.
The healthcare technology company said it now expects full-year revenue between $87 million and $93 million, down from an earlier projection of revenue between $95 million to $100 million.
Analysts polled by FactSet currently expect $96.2 million in full-year revenue.
"While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season," Chief Executive Stephen Silvestro said.
The company's third-quarter profit came in at $1.2 million, or 6 cents a share, compared with a profit of around $779,000, or 4 cents a share, a year earlier.
Stripping out certain one-time items, adjusted earnings were 20 cents a share. Analysts were expecting 16 cents a share.
Revenue fell to $21.6 million from $26.1 million a year prior. Analysts were expecting $21.2 million.
Comments